There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trillium Therapeutics (TRIL – Research Report), Zynex Inc (ZYXI – Research Report) and Viewray (VRAY – Research Report) with bullish sentiments.
Trillium Therapeutics (TRIL)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Trillium Therapeutics today and set a price target of $4. The company’s shares closed yesterday at $0.61, close to its 52-week low of $0.51.
“We maintain our Buy rating of TRIL and our 12-month price target of $4.00 per diluted share. We derive our price target based on a risk-adjusted net present value analysis of projected TTI-621 revenues through 2030 assuming a 12% discount rate and a 3% terminal growth rate. We derive an rNPV of and add C$65M in pro forma cash and cash equivalents to arrive at a 12-month price target of $4.19 per diluted share, which we round to $4.00.”
According to TipRanks.com, Ramakanth is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -9.2% and a 32.7% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Trillium Therapeutics with a $2.50 average price target.
Zynex Inc (ZYXI)
In a report released today, Marc Wiesenberger from B.Riley FBR maintained a Buy rating on Zynex Inc, with a price target of $9. The company’s shares closed yesterday at $5.57, close to its 52-week high of $5.90.
“Buy-rated Zynex, Inc. (ZYXI, $9 PT) reported 1Q results that continued its impressive turnaround story as the company posted its 11th consecutive quarter of positive net income. New orders for the company’s NexWave electrotherapy pain management device were up 30% and revenues of $9.2M easily topped management’s $8.3M-$8.8M guide despite a seasonally weaker 1Q in which healthcare deductibles generally remain unmet. The opioid epidemic plaguing the US has kept demand strong and reimbursement rates high for ZYXI’s NexWave, which according to management has no discernible side effects. Management appears to be boring full steam ahead with expansion of its sales force in order to fill the void left by the two largest players exiting the market at the end of 2015/early 2016.”
Wiesenberger has an average return of 54.5% when recommending Zynex Inc.
According to TipRanks.com, Wiesenberger is ranked #1580 out of 5198 analysts.
Zynex Inc has an analyst consensus of Moderate Buy, with a price target consensus of $7.
In a report released today, Andrew D’silva from B.Riley FBR reiterated a Buy rating on Viewray, with a price target of $12. The company’s shares closed yesterday at $6.96.
“ViewRay, Inc. (VRAY , $12 PT) reports 1Q19 results, and will host a conference call at 4:30 p.m. ET. (The dial-in/conference ID numbers are and 8616638, respectively.) We are comfortable with our/consensus’ top- and bottom-line estimates but note gross margins are a moving target and sales have the potential to be very lumpy: Revenue recognized from one MRIdian Linac can dramatically change a quarter’s results; VRAY has stringent revenue-recognition protocols that typically require the customer to acknowledge the system operates/meets product specifications. Thus, we believe it is best to evaluate VRAY on an annual basis and note our 2019 revenue estimate of $118.1M is near the midpoint of management’s $111M to $124M revenue guidance range.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 5.7% and a 35.8% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Sensus Healthcare Inc, and Anixa Biosciences Inc.
Viewray has an analyst consensus of Strong Buy, with a price target consensus of $13.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.